Latest features in GaBI Journal, 2016, Issue 3
Is the EU ready for non-biological complex drug products?
Biosimilars: achieving long-term savings and competitive markets
Current state of subsequent entry biologics (biosimilars) in Canada: a view from regulatory, reimbursement, clinician, and patient perspectives
The generic medicines system in Italy: scenarios for sustainable growth
Pharmacovigilance on biologicals and biosimilars: a Danish perspective
Regional management of biosimilars in Germany
Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?
Biosimilars in Italy: a gastroenterologist’s view
First Turkish interactive workshop on regulation and approval of similar biotherapeutic products/biosimilars, 2–3 March 2016, Ankara, Turkey
Demonstrating interchangeability and biosimilarity for US biosimilars
US FDA proposals for naming of biologicals and labelling of biosimilars
Competitive effects on the generics industry
Source URL: http://gabi-journal.net/20163-gabi-journal-table-of-contents.html
Copyright ©2022 GaBI Journal unless otherwise noted.